-
09:42:49 PM

CRBP Stock News

09/19/23 8:00 AM
Nasdaq : CRBP
conferencesclinical triallow float
Corbus Pharmaceuticals to Present Pre-Clinical Data Characterizing its CRB-701 Nectin-4 ADC at the at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Corbus Pharmaceuticals Holdings, Inc., a precision oncology company, today announced the pre-clinical data on its CRB-701 Nectin-4 anti-drug-conjugate will be presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, to be held in Boston, MA October 11-15, 2023..
RHEA-AI
neutral
08/08/23 8:00 AM
Nasdaq : CRBP
earningslow float
Corbus Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
CRB-701 Phase 1 trial in China is ahead of schedule with dose escalation completion expected Q4 2023 and U.S. clinical trial start planned for Q1 2024 Preliminary clinical PK data indicates CRB-701 has a longer half-life and reduced levels of circulating free MMAE relative to published data for PADCEV ® CRB-601 IND submission is on track for Q4 2023.
RHEA-AI
neutral
05/09/23 8:00 AM
Nasdaq : CRBP
earningslow float
Corbus Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
Company expanded precision oncology pipeline with in-licensing of CRB-701: a clinical-stage Nectin-4 antibody drug conjugate from CSPC Pharmaceutical Group CRB-701 Phase 1 dose escalation study ongoing in patients with advanced solid tumors in China Presented latest CRB-601 anti-αvβ8 mAb pre-clinical data at American Association of Cancer...
RHEA-AI
neutral
05/01/23 8:00 AM
Nasdaq : CRBP
conferencesclinical triallow float
Corbus Pharmaceuticals to Present Latest Pre-Clinical Data on CRB-601 avβ8 Blocking Antibody at the New York Academy of Sciences' Frontiers in Cancer Immunotherapy Meeting
Corbus Pharmaceuticals Holdings, Inc., a precision oncology company, today announced that an abstract highlighting pre-clinical data for CRB-601, its avβ8 blocking antibody, has been accepted for oral presentation in the main program of the New York Academy of Sciences' 2023 Frontiers in Cancer Immunotherapy meeting,...
RHEA-AI
neutral
04/17/23 8:30 AM
Nasdaq : CRBP
clinical triallow float
Corbus Pharmaceuticals Presents Latest Pre-Clinical Data on CRB-601 at the 2023 American Association for Cancer Research Annual Meeting
CRB-601 shows dose-dependent antitumor activity correlating with increased binding to αvβ8 in pre-clinical tumor models CRB-601 enhances anti-PD-1 immunotherapy efficacy and induces long-lasting tumor-specific cytotoxic T-cells IND submission for CRB-601 on track for 2H 2023 NORWOOD, Mass. , April
RHEA-AI
neutral
03/14/23 4:35 PM
Nasdaq : CRBP
low float
Corbus Pharmaceuticals Data on CRB-601 avβ8 Blocking Antibody Accepted for Presentation at the America Association for Cancer Research Annual Meeting
Corbus Pharmaceuticals Holdings, Inc., a precision oncology company, today announced that an abstract highlighting pre-clinical data for CRB-601, its avβ8 blocking antibody, has been accepted for presentation at a poster at the 2023 American Association for Cancer Research annual meeting, to be held April 14-19, 2023 in Orlando, Fl.. Poster Presentation...
RHEA-AI
neutral